Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective Mohamed Ben-EltrikiGehana ShankarSubrata Deb Review Article 15 September 2023 Pages: 419 - 437
Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy Mohamed J. SaadhMuhammad Ali Abdulllah AlmoyadReza Akhavan-Sigari Review Article 28 September 2023 Pages: 439 - 453
An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose Bart A. JessenPaul CornwellTimothy Hart Original Article Open access 28 July 2023 Pages: 455 - 464
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer Yukitaka ShibataNatsumi MatsumotoKen-ichi Fujita Original Article 31 August 2023 Pages: 465 - 474
Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients Alireza AbbaspourMehdi DehghaniOmidreza Firuzi Original Article 05 September 2023 Pages: 475 - 483
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models Martina JabloñskiMaría Sol RodríguezIsabel Alicia Lüthy Original Article 19 September 2023 Pages: 485 - 499
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes Anna Maria MilitelloGiulia OrsiMichele Reni Original Article 19 September 2023 Pages: 501 - 510